The Novartis inspection site will be closed by the end of 2023 due to an erosion in demand, the multinational confirmed on Wednesday. A consultation procedure with employees has been initiated.
Novartis confirms in a position paper on Wednesday its intention to close Pharmanalytica, its inspection site in Lugano, by the end of 2023, due to an erosion of demand calling into question its competitiveness.
The measure threatens the jobs of around fifty employees. The gesture responds to the pharmaceutical giant’s reorientation towards specialized and personalized products, which do not require the same standardized examination procedures as high-volume products.
The pharmaceutical giant has initiated a consultation procedure with employees and managers of the Ticino site and ensures that a social plan including compensation, early retirement or support in finding new jobs will be put in place.
Help for employees
At the microphone of the RSI, the person in charge of the Locarnais site Leandro Checchinato affirmed that he would do all that is reasonably possible “to help our employees to face this difficult moment”.
In September 2018, the Rhine multinational announced its intention to cut some 2,200 jobs in Switzerland over the next four years, including 1,500 in production.
Founded in 1937
Founded in 1937 under the name Chemie Lautenberg, Pharmanalytica entered the fold of Sandoz in the 1970s, then of Novartis after the merger with Ciba-Geigy in 1996.
A few years ago, Pharmanalytica employed around one hundred people, or around a third of the total workforce of the twenty or so chemical-pharmaceutical companies present in the Locarno region, recalls the RSI.